세계의 맞춤형 항체 시장 평가 : 유형별, 서비스별, 유래별, 연구 분야별, 용도별, 최종사용자별, 지역별, 기회, 예측(2017-2031년)

Global custom antibody market is projected to witness a CAGR of 9.53% during the forecast period 2024-2031F, growing from USD 451.88 million in 2023 to USD 936.25 million in 2031F. The growth of the market is bolstered by increasing cases of various chronic conditions, rising requirement for precision medicine, and increasing research and development activities.

The rising cases of infectious and autoimmune diseases, and cancer are bolstering the global custom antibody market size. Monoclonal and polyclonal antibodies aid in managing, treating, and diagnosing such diseases due to their affinity for multiple antigens. Biochemists and researchers use polyclonal antibodies to analyze biological samples, thus propelling the market demand. The rapid expansion of the healthcare sector is also supporting the growth of the market as custom antibodies play a vital role in clinical research by allowing the researchers to determine the effectiveness of different vaccines and therapeutics.

The increasing investments by companies towards the expansion of their manufacturing facilities is another major factor supporting the growth of the market. In August 2022, Absolute Antibody Ltd, one of the leading providers of recombinant services and products, announced the expansion of its manufacturing facility in northeast England. This expansion is expected to aid the company in providing enhanced services to its customers and support the expansion of its recombinant antibody portfolio. The company's custom antibody expression, sequencing, and engineering services are utilized by various diagnostic, biotechnology, and pharmaceutical companies and academic institutes across the globe. Such expansions are expected to aid the companies in expanding their presence and support the market's expansion. Additionally, various market players are also investing in acquisitions to enhance their global presence. For instance, in April 2024, Sino Biological, Inc. announced the accusation of SignalChem Biotech Inc. in a USD 48 million deal. The latter's acquisition will aid Sino in boosting its presence in bioactive recombinant proteins contract research services.

Rising Investments Towards Research and Development Supports Market Expansion

The growing investments by various biotechnology companies in research and development activities are expected to positively influence the growth of the market in the coming years. In October 2022, Taconic Biosciences, Inc. launched the first super immunodeficient mouse model that lacks residual murine Fc gamma receptors. The FcResolv NOG models provide enhanced clarity in antibody-based drug studies, ensuring the availability of more transferable data with fewer animals and studies. The model is viable for engrafting a diverse range of tissues and human cells and has applications in autoimmune diseases, immune-oncology, and oncology. The NOG portfolio provided by the company will aid researchers in evaluating drug candidates without interference from residual murine Fc gamma receptors and eliminate false negatives. The portfolio also eliminates the deconvolution steps required for distinguishing the efficacy of the drugs from the mouse immune system-mediated off-target effects, allowing researchers to use drug discovery investments in an effective manner.

Increasing Requirement for Precision Medicine Supports Market Growth

The increasing popularity of precision medicine in different regions across the globe can be attributed to their ability to consider the variability in the lifestyle, environment, and genes of every individual. This treatment strategy ensures that preventive and therapeutic interventions are provided to patients that aid in reducing costs and maximize health benefits and span across a broad range of arenas that include casual inference, genetics and genomics, health communication, and drug discovery. The antibody-based precision medicines use monoclonal antibodies for targeting disease-causing molecules. Monoclonal antibodies can provide effective and targeted therapies that have fewer side effects in comparison to the traditional treatment options because they target specific molecules that are involved with the progression or development of the disease. Additionally, precision medicine also plays a crucial role in autoimmune disorders that demonstrate both molecular and clinical variability. According to the estimates from the Johns Hopkins Medicine, autoimmune diseases affect approximately 3% of the population of the United States. Thus, the increasing prevalence of such diseases is further providing lucrative growth opportunities to the market.

North America Accounts for Significant Market Share

The market's expansion in the region can be attributed to the strong presence of key market players, expansion of the healthcare and pharmaceutical sectors, and the increasing investments in research and development activities. The rapid growth of the biotechnology sector in the region due to rising research activities in the biopharmaceutical sector and increasing prevalence of chronic diseases is also providing lucrative growth opportunities to the market. According to the estimates of the Canadian Cancer Society, in 2024, approximately 247,100 new cases and 88,100 deaths related to cancer are expected to occur in Canada.

Furthermore, the increasing investments by leading market players in the region are also providing lucrative growth opportunities for the market. In October 2023, Sino Biological, Inc. announced the opening of their new center for Bioprocessing in Houston, United States, adjacent to the renowned Texas Medical Center. The center is going to specialize in contract research services, including recombinant antibody and recombinant protein manufacture and development. The center will also focus on the production and development of diagnostic and research grade proteins and antibodies by using mammalian cells and will aid the biotechnology company in expanding their global presence.

Oncology Expected to Witness Significant Growth

The rising prevalence of cancer in various regions across the globe is propelling the demand for custom antibodies in the global market. As per the estimates of the American Cancer Society, approximately 2,001,140 new cases and 611,720 deaths are expected to occur because of cancer in 2024. Monoclonal custom antibodies are capable of causing the death of tumor cells via a wide range of mechanisms. The direct mechanism involves blocking the growth factor receptor signaling to induce tumor cell death. In various types of cancer, the overexpression of epidermal growth factor receptor (EGFR) occurs, which results in the proliferation of tumor cells. With the help of an anti-EGFR monoclonal antibody, the dimerization of the receptor occurs, which blocks ligand binding, leading to the apoptosis of tumor cells.

Future Market Scenario (2024-2031F)

According to the global custom antibody market analysis, the rising cases of cancer, infectious diseases, autoimmune diseases, and cardiovascular diseases over the coming years in different regions across the globe are expected to provide lucrative growth opportunities to the market. Custom antibodies are also expected to aid in improving the accuracy of various diagnostic tests, allowing for early detection of diseases while aiding in the development of novel therapies. Over the forecast period, they are expected to play a pivotal role in the study of specific cellular processes and pathways and support the development of personalized medicines for targeting specific diseases.

Key Players Landscape and Outlook

The rising investments by leading market players towards service partnerships are boosting the global custom antibody market growth. In April 2024, Sino Biological, Inc., known for providing biological research agents, announced a service partnership with Rapid Novor, Inc. The former is going to market Rapid's proprietary REmAb monoclonal antibody sequencing services in South Korea, China, Japan, Vietnam, Philippines, Indonesia, Malaysia, Thailand, and Singapore. With this partnership, Sino's clients will have access to accurate sequencing with the help of Rapid's REmAb technology. Such partnerships are expected to aid market players in expanding their customer base and ensure the provision of advanced technological solutions.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Custom Antibody Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. By Type
  • 4.2.1. Monoclonal Antibodies
  • 4.2.2. Polyclonal Antibodies
  • 4.2.3. Recombinant Antibodies
  • 4.2.4. Others
• 4.3. By Service
  • 4.3.1. Antibody Development
    • 4.3.1.1. Antigen Preparation
    • 4.3.1.2. Antibody Characterization
    • 4.3.1.3. Immunization and Hybridoma Production
  • 4.3.2. Antibody Production and Purification
  • 4.3.3. Antibody Fragmentation and Labeling
• 4.4. By Source
  • 4.4.1. Mice
  • 4.4.2. Rabbits
  • 4.4.3. Others
• 4.5. By Research Area
  • 4.5.1. Immunology
  • 4.5.2. Neurobiology
  • 4.5.3. Oncology
  • 4.5.4. Infectious Diseases
  • 4.5.5. Cardiovascular Diseases
  • 4.5.6. Others
• 4.6. By Application
  • 4.6.1. Therapeutics
  • 4.6.2. Research
• 4.7. By End-users
  • 4.7.1. Pharmaceutical and Biotechnology Companies
  • 4.7.2. Contract Research Organizations
  • 4.7.3. Research and Academic Institutions
• 4.8. By Region
  • 4.8.1. North America
  • 4.8.2. South America
  • 4.8.3. Europe
  • 4.8.4. Asia-Pacific
  • 4.8.5. Middle East and Africa
• 4.9. By Company Market Share (%), 2023

5. Global Custom Antibody Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
  • 5.1.2. By Type
    • 5.1.2.1. Monoclonal Antibodies
    • 5.1.2.2. Polyclonal Antibodies
    • 5.1.2.3. Recombinant Antibodies
    • 5.1.2.4. Others
  • 5.1.3. By Service
    • 5.1.3.1. Antibody Development
      • 5.1.3.1.1. Antigen Preparation
      • 5.1.3.1.2. Antibody Characterization
      • 5.1.3.1.3. Immunization and Hybridoma Production
    • 5.1.3.2. Antibody Production and Purification
    • 5.1.3.3. Antibody Fragmentation and Labeling
  • 5.1.4. By Source
    • 5.1.4.1. Mice
    • 5.1.4.2. Rabbits
    • 5.1.4.3. Others
  • 5.1.5. By Research Area
    • 5.1.5.1. Immunology
    • 5.1.5.2. Neurobiology
    • 5.1.5.3. Oncology
    • 5.1.5.4. Infectious Diseases
    • 5.1.5.5. Cardiovascular Diseases
    • 5.1.5.6. Others
  • 5.1.6. By Application
    • 5.1.6.1. Therapeutics
    • 5.1.6.2. Research
  • 5.1.7. By End-users
    • 5.1.7.1. Pharmaceutical and Biotechnology Companies
    • 5.1.7.2. Contract Research Organizations
    • 5.1.7.3. Research and Academic Institutions
  • 5.1.8. United States*
    • 5.1.8.1. Market Size & Forecast
      • 5.1.8.1.1. By Value
    • 5.1.8.2. By Type
      • 5.1.8.2.1. Monoclonal Antibodies
      • 5.1.8.2.2. Polyclonal Antibodies
      • 5.1.8.2.3. Recombinant Antibodies
      • 5.1.8.2.4. Others
    • 5.1.8.3. By Service
      • 5.1.8.3.1. Antibody Development
        • 5.1.8.3.1.1. Antigen Preparation
        • 5.1.8.3.1.2. Antibody Characterization
        • 5.1.8.3.1.3. Immunization and Hybridoma Production
      • 5.1.8.3.2. Antibody Production and Purification
      • 5.1.8.3.3. Antibody Fragmentation and Labeling
    • 5.1.8.4. By Source
      • 5.1.8.4.1. Mice
      • 5.1.8.4.2. Rabbits
      • 5.1.8.4.3. Others
    • 5.1.8.5. By Research Area
      • 5.1.8.5.1. Immunology
      • 5.1.8.5.2. Neurobiology
      • 5.1.8.5.3. Oncology
      • 5.1.8.5.4. Infectious Diseases
      • 5.1.8.5.5. Cardiovascular Diseases
      • 5.1.8.5.6. Others
    • 5.1.8.6. By Application
      • 5.1.8.6.1. Therapeutics
      • 5.1.8.6.2. Research
    • 5.1.8.7. By End-users
      • 5.1.8.7.1. Pharmaceutical and Biotechnology Companies
      • 5.1.8.7.2. Contract Research Organizations
      • 5.1.8.7.3. Research and Academic Institutions
  • 5.1.9. Canada
  • 5.1.10. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East and Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Type
• 6.2. By Service
• 6.3. By Source
• 6.4. By Research Area
• 6.5. By Application
• 6.6. By End-users
• 6.7. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat From New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Patent Landscape
• 9.2. Regulatory Approvals
• 9.3. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Thermo Fisher Scientific Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products and Services
  • 13.1.4. Financials (As Reported)
  • 13.1.5. Key Market Focus and Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Bio-Rad Laboratories, Inc.
• 13.3. Danaher Corporation
• 13.4. Agilent Technologies, Inc.
• 13.5. BioLegend, Inc.
• 13.6. GenScript Biotech Corporation
• 13.7. RayBiotech, Inc.
• 13.8. Cell Signaling Technology, Inc.
• 13.9. ProMab Biotechnologies, Inc.
• 13.10. Sino Biological, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer